Is HCW Biologics Inc. (HCWB) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2024
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 383.5% / 30% | 130.9% / 30% | 16.3% / 30% | 3.39% / 5% | ✗ NOT HALAL |
| DJIM | 383.5% / 33% | 130.9% / 33% | 16.3% / 33% | 3.39% / 5% | ✗ NOT HALAL |
| MSCI | 45.3% / 33% | 15.5% / 33% | 1.9% / 33% | 3.39% / 5% | ✗ NOT HALAL |
| S&P | 383.5% / 33% | 130.9% / 33% | 16.3% / 33% | 3.39% / 5% | ✗ NOT HALAL |
| FTSE | 45.3% / 33% | 15.5% / 33% | 1.9% / 50% | 3.39% / 5% | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | 20.0% | |
| Operating Margin | -21095.3% | |
| Net Margin | 0.0% | |
| Return on Assets (ROA) | -31.7% |
Cash Flow & Balance Sheet
| Operating Cash Flow | -$14M |
| Free Cash Flow | -$14M |
| Total Debt | $14M |
| Current Ratio | 0.1 |
| Total Assets | $30M |
Price & Trading
| Last Close | $0.37 |
| 50-Day MA | $0.82 |
| 200-Day MA | $2.87 |
| Avg Volume | 8.5M |
| Beta | 0.8 |
|
52-Week Range
$0.36
| |
About HCW Biologics Inc. (HCWB)
HCW Biologics Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel immunotherapies for chronic, low-grade inflammation, and age-related diseases in the United States. The company's lead products include HCW9218, a clinical-stage bifunctional molecule, which has completed Phase 1 to treat chemotherapy-refractory solid tumor cancers and Phase 1b/2 to treat pancreatic cancer; and HCW9302, injectable and interleukin 2 (IL-2) fusion protein complex, which is in phase 1 for autoimmune and proinflammatory diseases, such as alopecia areata diseases. It also develops HCW9201 and HCW9206, novel immunotherapeutic for memory-like natural killer cells, cancer, and pathogens; HCW11-006, an immune cell stimulator; HCW11-002 and HCW11-0027, which are immune checkpoint inhibitors to treat oncology and other senescence-associated indications; and HCW11-018, a fusions and immune cell engagers to treat cancer. The company has a license agreement with Wugen Inc. to develop cell therapy-based treatments; and a license, research and co-development agreement with WY Biotech Co., Ltd. for its preclinical molecules. HCW Biologics Inc. was incorporated in 2018 and is headquartered in Miramar, Florida.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is HCW Biologics Inc. (HCWB) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), HCW Biologics Inc. is Not Halal. The company fails one or more screening criteria. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is HCW Biologics Inc.'s debt ratio?
HCW Biologics Inc.'s debt ratio is 383.5% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 45.3%.
What are HCW Biologics Inc.'s key financial metrics?
HCW Biologics Inc. has a market capitalization of $2M, and revenue of $3M.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.